Scarica l'app Stockscreener
87.19
2.75%
2.505
Panoramica
Notizia
Cronologia dei prezzi
Catena di opzioni
Financials
Perché DXCM Giù?
Forum
Previsione
Frazionamento azionario
Precedente Chiudi:
$84.68
Aprire:
$84.04
Volume 24 ore:
1.74M
Relative Volume:
0.37
Capitalizzazione di mercato:
$32.89B
Reddito:
$4.82B
Utile/perdita netta:
$930.40M
Rapporto P/E:
37.29
EPS:
2.3381
Flusso di cassa netto:
$1.43B
1 W Prestazione:
+2.93%
1M Prestazione:
-3.06%
6M Prestazione:
+35.44%
1 anno Prestazione:
+15.12%
Intervallo 1D:
$83.25
$87.21
Intervallo di 1 settimana:
$82.29
$87.07
Portata 52W:
$54.11
$92.59
Dexcom Inc Stock (DXCM) Company Profile
Nome
Dexcom Inc
Settore
Industria
Telefono
(858) 200-0200
Indirizzo
6340 SEQUENCE DRIVE, SAN DIEGO, CA
Compare DXCM vs ABT, MDT, SYK, BSX, EW
| Azioni | Prezzo | Cap. di mercato | Reddito | Reddito netto | Flusso di cassa | EPS |
|---|---|---|---|---|---|---|
DXCM
Dexcom Inc
|
87.17 | 31.33B | 4.82B | 930.40M | 1.43B | 2.3381 |
ABT
Abbott Laboratories
|
102.37 | 176.41B | 46.59B | 5.41B | 7.38B | 3.0938 |
MDT
Medtronic Plc
|
94.47 | 116.35B | 36.36B | 4.84B | 5.43B | 3.7261 |
SYK
Stryker Corp
|
282.18 | 105.70B | 25.27B | 3.34B | 4.57B | 8.6334 |
BSX
Boston Scientific Corp
|
44.25 | 62.29B | 20.62B | 3.56B | 3.48B | 2.3847 |
EW
Edwards Lifesciences Corp
|
85.89 | 48.63B | 6.30B | 1.07B | 1.09B | 1.8406 |
Dexcom Inc Stock (DXCM) Upgrades & Downgrades
| Data | Azione | Analista | Modifica della valutazione |
|---|---|---|---|
| 2026-03-24 | Aggiornamento | Evercore ISI | In-line → Outperform |
| 2026-01-12 | Downgrade | Barclays | Equal Weight → Underweight |
| 2025-12-02 | Aggiornamento | Morgan Stanley | Equal-Weight → Overweight |
| 2025-11-25 | Iniziato | Evercore ISI | In-line |
| 2025-10-21 | Ripresa | Stifel | Buy |
| 2025-09-08 | Downgrade | Oppenheimer | Outperform → Perform |
| 2025-08-21 | Iniziato | Argus | Buy |
| 2025-06-16 | Iniziato | Truist | Buy |
| 2025-05-30 | Iniziato | Goldman | Buy |
| 2025-04-10 | Iniziato | Mizuho | Outperform |
| 2025-02-03 | Aggiornamento | Redburn Atlantic | Neutral → Buy |
| 2025-01-16 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2024-07-26 | Downgrade | JP Morgan | Overweight → Neutral |
| 2024-07-26 | Downgrade | Robert W. Baird | Outperform → Neutral |
| 2024-05-30 | Iniziato | Redburn Atlantic | Neutral |
| 2024-03-12 | Iniziato | RBC Capital Mkts | Outperform |
| 2023-05-30 | Ripresa | Morgan Stanley | Equal-Weight |
| 2023-04-17 | Aggiornamento | Raymond James | Outperform → Strong Buy |
| 2023-03-29 | Iniziato | UBS | Buy |
| 2023-01-26 | Iniziato | Wolfe Research | Outperform |
| 2022-10-18 | Iniziato | Barclays | Equal Weight |
| 2022-10-12 | Iniziato | Jefferies | Buy |
| 2022-07-15 | Iniziato | Bernstein | Outperform |
| 2022-03-02 | Ripresa | BofA Securities | Buy |
| 2022-02-03 | Aggiornamento | BTIG Research | Neutral → Buy |
| 2022-01-19 | Aggiornamento | Wells Fargo | Equal Weight → Overweight |
| 2022-01-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2021-10-18 | Downgrade | Guggenheim | Buy → Neutral |
| 2021-07-21 | Ripresa | Cowen | Outperform |
| 2021-05-28 | Aggiornamento | Wells Fargo | Underweight → Equal Weight |
| 2021-05-25 | Iniziato | Barclays | Overweight |
| 2021-04-15 | Iniziato | Atlantic Equities | Overweight |
| 2021-01-06 | Aggiornamento | UBS | Neutral → Buy |
| 2020-10-02 | Downgrade | Wells Fargo | Equal Weight → Underweight |
| 2020-05-27 | Reiterato | Piper Sandler | Overweight |
| 2020-05-14 | Iniziato | Wells Fargo | Equal Weight |
| 2020-03-05 | Iniziato | Citigroup | Buy |
| 2019-11-07 | Reiterato | Canaccord Genuity | Buy |
| 2019-11-07 | Aggiornamento | Guggenheim | Neutral → Buy |
| 2019-10-23 | Iniziato | Stifel | Buy |
| 2018-11-28 | Iniziato | UBS | Neutral |
| 2018-10-19 | Aggiornamento | Goldman | Sell → Neutral |
| 2018-09-12 | Aggiornamento | Northland Capital | Under Perform → Market Perform |
| 2018-08-02 | Reiterato | Canaccord Genuity | Buy |
| 2018-07-02 | Aggiornamento | Raymond James | Mkt Perform → Outperform |
| 2018-06-08 | Aggiornamento | JP Morgan | Neutral → Overweight |
| 2018-05-11 | Iniziato | BofA/Merrill | Buy |
| 2018-05-03 | Reiterato | Canaccord Genuity | Buy |
| 2018-04-04 | Iniziato | Goldman | Sell |
| 2018-04-04 | Iniziato | Guggenheim | Neutral |
| 2018-03-23 | Aggiornamento | Robert W. Baird | Neutral → Outperform |
| 2018-01-04 | Downgrade | Northland Capital | Market Perform → Under Perform |
| 2017-09-28 | Reiterato | Wedbush | Outperform |
Mostra tutto
Dexcom Inc Borsa (DXCM) Ultime notizie
DexCom Inc Share PriceDXCM, RNS News, Articles, Quotes, & Charts (NASDAQ:DXCM) - Proactive financial news
DexCom Inc. stock underperforms Friday when compared to competitors - MarketWatch
DexCom (DXCM) Expands Board to 13 Directors with Appointment of Glenn S. Boehnlein - GuruFocus
Dexcom stock heads into the open after a 0.8% Nasdaq pullback - ad-hoc-news.de
Dexcom Appoints Glenn Boehnlein to Board of Directors - BioSpace
DexCom Expands Board with Glenn Boehnlein Appointment and Details Compensation Plan - Kalkine Media
DexCom, Inc. Announces Appointment of Glenn S. Boehnlein as Director, Member of Operations & Innovation Committee and Audit Committee, Effective September 10, 2026 - marketscreener.com
Dexcom (NASDAQ: DXCM) director gets 5,841-unit stock grant vesting over 3 years - Stock Titan
Dexcom (DXCM) director discloses 42-share trust stake - Stock Titan
DexCom, Inc. (DXCM) latest stock news and headlines - Yahoo Finance UK
DexCom appoints Glenn S. Boehnlein to Board and committees - TradingView
Dexcom (NASDAQ: DXCM) officer lines up six‑figure stock sale - Stock Titan
How Dexcom Inc. (DXCM) Affects Rotational Strategy Timing - Stock Traders Daily
Dexcom Inc. stock steadies near mid-range as conference outlines growth plan - ad-hoc-news.de
DexCom expects CONNECT study on type 2 diabetes to be published soon in a major journal. - Pluang
Dexcom at Wells Fargo conference: coverage push drives growth plan By Investing.com - Investing.com India
Transcript : DexCom, Inc. Presents at Wells Fargo 21st Annual Healthcare Conference, Sep-09-2026 08:00 AM - marketscreener.com
DexCom Stock: Is DXCM Underperforming the Healthcare Sector? - webull.com
Dexcom stock heads into the open after a 3.8 percent drop - ad-hoc-news.de
Kakao Healthcare Lends Glucose Monitors to Diabetic Exam Takers - Seoul Economic Daily
DexCom Inc (DXCM) Shares Fall 3.8% -- What GF Score of 95 Tells Investors - GuruFocus
DexCom Inc. stock underperforms Tuesday when compared to competitors - MarketWatch
Law firm probes DexCom officers for possible br... - Pluang
Did DexCom, Inc. Insiders Breach their Fiduciary Duties to Shareholders? - PR Newswire
DexCom, Inc. (DXCM) Stock Analysis: A Strong Buy With 7% Upside Potential - DirectorsTalk Interviews
Dexcom Inc. stock holds near consensus target on solid Q2 2026 growth - ad-hoc-news.de
Dexcom stock holds near USD 89.71 after strong Q2 - AD HOC NEWS
DexCom (DXCM) Stock Looks Undervalued On Fair Value While Earnings Look Fair - Yahoo Finance
Q2 Earnings Highs And Lows: DexCom (NASDAQ:DXCM) Vs The Rest Of The Patient Monitoring Stocks - finance.yahoo.com
Revisiting Stock Picks Dexcom, Bristol Myers Squibb, Quanta Services - Barron's
ETFs Investing in DexCom, Inc. Stocks - TradingView
Why DexCom (DXCM) is a Top Growth Stock for the Long-Term - Eastern Progress
DexCom Inc. stock outperforms competitors despite losses on the day - MarketWatch
3 Reasons DXCM Has Explosive Upside Potential - finance.yahoo.com
Here's How Much a $1000 Investment in DexCom Made 10 Years Ago Would Be Worth Today - qz.com
Dexcom Announces Upcoming Conference Presentation - Business Wire
G7 Momentum and Global Reach Might Change The Case For Investing In DexCom (DXCM) - simplywall.st
DexCom, Inc. (DXCM) Stock Analysis: Strong Buy Ratings And A Promising 3.63% Upside - DirectorsTalk Interviews
Dexcom (DXCM) HR chief cashes out 2,565 company shares - stocktitan.net
Dexcom Defeats Investor Suit Over Glucose Monitor Market Share - Bloomberg Law News
FDA Approves Abbott's First Wearable Device for Dual Ketone and Glucose Tracking - Sahm
DexCom (NASDAQ: DXCM) officer may sell 2,565 shares on Aug. 27, 2026 - Stock Titan
We Ran A Stock Scan For Earnings Growth And DexCom (NASDAQ:DXCM) Passed With Ease - Moomoo
Dexcom (NASDAQ: DXCM) officer keeps 101,502 shares after tax withholding - Stock Titan
Abbott vs. DexCom: Which CGM Stock Is the Better Buy Now? - Eastern Progress
Dexcom (NASDAQ: DXCM) CEO retains 418,908 shares after tax withholding - Stock Titan
Dexcom (NASDAQ: DXCM) chair sells 26,756 shares around $90 - Stock Titan
Bronstein, Gewirtz & Grossman, LLC Encourages DexCom, Inc. (DXCM) - The National Law Review
DexCom (NASDAQ:DXCM) Reaches New 52-Week HighStill a Buy? - MarketBeat
DexCom stock hits 52-week high at 91.99 USD - Investing.com
DexCom Study Demonstrates CGM Benefits in Type 2 Diabetes - Medical Product Outsourcing
Dexcom Inc Azioni (DXCM) Dati Finanziari
Reddito
Reddito netto
Flusso di cassa
EPS
Dexcom Inc Azioni (DXCM) insider trading
| Commercio interno | Relazione | Data | Transazione | Costo | #Azioni | Valore ($) | #Azioni Totale |
|---|---|---|---|---|---|---|---|
| Stern Sadie | EVP Chief People & Culture Off |
Aug 27 '26 |
Sale |
88.37 |
2,565 |
226,669 |
126,043 |
0.01%
1.55%
Apri su Yahoo
|
Apri su Google
|
Aperto in Finviz
|
Apri in MarketWatch
|
Aperto a EDGAR
|
Aperto su Reuters
Capitalizzazione:
|
Volume (24 ore):